PFE Ticker Curator

• High volume: 179.18K contracts traded, calls at 74.09% vs puts 25.91%.
• Steady open interest: 2.52M contracts, 97.57% of 30-day average.
• Top...

Short-term sentiment gauge via options flow:

• Shares down 8c to ~$26.84 with mixed options sentiment
• Volume normal at 52k contracts, calls...

Big Pharma pipelines diverging amid complexity:

• Companies specializing in strengths like oncology over broad targets
• PFE held largest pipeline last year; Roche now leads with 262 drugs
• AstraZeneca oncology-dominant, Sanofi vaccine-focused

Pfizer (PFE) makes the cut as one of four top Big Pharma stocks resilient amid rising geopolitical tensions like failed U.S.-Iran talks. These picks...

Key genetic insights from 28,000 GLP-1 users:

• GLP1R variant adds ~0.7kg weight loss per copy; GIPR raises tirzepatide vomiting risk
• Side effects...

Pfizer's digital push continues: Renewed licensing with Trellus Health for patient support content in its IBD app, originally signed Q2 2024.
-...

BMO Capital has raised its Pfizer (PFE) price target to $34 from $30, maintaining an Outperform rating – signaling growing optimism on valuation. PFE traded down 1.10% amid the update.

Pfizer partnership renewal keeps Trellus IBD content in its digital app, validating resilience methodology across pharma lifecycle.

• Cash runway...

Institutional Ownership Changes

• 🔥 Robeco Trims Stake: Robeco Institutional Asset Management trimmed its Pfizer stake by 13.4%, now holding...

Bispecific antibody market exploding from $12.4B (2025) to $82.3B (2034) at 23.1% CAGR.

• North America dominates with 47.2% share ($5.9B), led by...

Healthcare stocks like Pfizer draw attention amid tech woes and fading AI hype.

• Post-vaccine revenue steady: $59.5-62.5B forecast for 2026, matching...

• Sidewinder Therapeutics: $137M to develop bispecific ADCs binding two tumor targets for better specificity and reduced side effects, targeting...

Pfizer's swift strategic shift:

• Transitioned SEO and AI discoverability to in-house team this week after 60-day buildout with new hires like...

Key institutional moves in PFE:

• Robeco Institutional Asset Management sold 1.53M shares (13.4% trim), holding 9.87M shares worth $245.78M (0.17%...

Emerging Q4 selling pattern in PFE despite steady 68.36% institutional ownership:

• Sumitomo Mitsui trimmed 3.1% (483k shares sold), holding 15M...

Eli Lilly has a clearer path ahead as a 2026 buy vs Pfizer, despite both sharing exciting growth opportunities—PFE's deals could take time to pay off.

Institutional Ownership Changes

• Ritholtz Wealth Management Buys Shares: Ritholtz Wealth Management increased its stake in Pfizer by 51.5% in Q4,...

Positive institutional signal for undervalued PFE:

• Ritholtz buys 60,645 shares in Q4, hiking stake 51.5% to 178,481 shares ($4.444M).
• Institutions...

Key differences highlighted:

• JNJ's edge: Kenvue spin-off drove efficiency, revenue at $88.8B in 2024, projected $99.5-100.5B by 2026.
• PFE hurdles:...

• Flu/RSV pipelines fuel mRNA market growth to 2035, reshaping 65% infectious disease segment from COVID dominance.
• Pfizer listed among key players...